Mechanisms of action of TGF-β in cancer: Evidence for Smad3 as a repressor of the hTERT gene

Annals of the New York Academy of Sciences

Volumn 1114, Issue , 2007, Pages 56-68

  Li, He ^a,b   Liu, Jun Ping ^a,b  

^a MONASH UNIVERSITY   (Australia)

^b MONASH UNIVERSITY MEDICAL SCHOOL   (Australia)

Author keywords

Cancer; hTERT; Inhibition; Smad3; Telomerase; Telomeres; TGF beta; Tumorigenesis

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; MYC PROTEIN; SMAD3 PROTEIN; TELOMERASE REVERSE TRANSCRIPTASE; TRANSFORMING GROWTH FACTOR BETA;

BREAST CANCER; CANCER; CANCER CELL; CELL NUCLEUS; CELL PROLIFERATION; CONFERENCE PAPER; DRUG MECHANISM; ENZYME ACTIVITY; EVIDENCE BASED MEDICINE; FEEDBACK SYSTEM; GENE INTERACTION; GENE REPRESSION; GENETIC TRANSCRIPTION; HUMAN; LIFESPAN; NONHUMAN; ONCOGENE C MYC; PROMOTER REGION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR GROWTH;

EID: 35948943138     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1396.016     Document Type: Conference Paper

References (76)

1. MOSES, H.L. et al. 1990. TGF-beta stimulation and inhibition of cell proliferation: new mechanistic insights. Cell 63: 245-247.
2. LIN, S.Y. et al. 2003. Regulation of ovarian function by the TGF-beta superfamily and follistatin. Reproduction 126: 133-148.
3. FINDLAY, J.K. et al. 2002. Recruitment and development of the follicle; the roles of the transforming growth factor-beta superfamily. Mol. Cell Endocrinol. 191: 35-43.
4. RUSSO, L.M. et al. 2002. Albuminuria in hypertension is linked to altered lysosomal activity and TGF-beta1 expression. Hypertension 39: 281-286.
5. WAKEFIELD, L.M. & A.B. ROBERTS. 2002. TGF-[beta] signaling: positive and negative effects on tumorigenesis. Curr. Opin. Genet. Dev. 12: 22-29.
6. FANAYAN, S. et al. 2002. Signaling through the Smad pathway by insulin-like growth factor-binding protein-3 in breast cancer cells. Relationship to transforming growth factor-beta 1 signaling. J. Biol. Chem. 277: 7255-7261.
7. SHI, Y. & J. MASSAGUE. 2003. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113: 685-700.
8. KIM, S.J. et al. 2000. Molecular mechanisms of inactivation of TGF-[beta] receptors during carcinogenesis. Cytokine Growth Factor Rev. 11: 159-168.
9. HAHN, S.A. et al. 1996. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 271: 350-353.
10. YANAGISAWA, K. et al. 2000. Heterogeneities in the biological and biochemical functions of Smad2 and Smad4 mutants naturally occurring in human lung cancers. Oncogene 19: 2305-2311.
11. HAN, S.U. et al. 2004. Loss of the Smad3 expression increases susceptibility to tumorigenicity in human gastric cancer. Oncogene 23: 1333-1341.
12. ZAVADIL, J. et al. 2004. Integration of TGF-beta/Smad and Jagged1/Notch signalling in epithelial-to-mesenchymal transition. EMBO J. 23: 1155-1165.
13. ZHU, Y. et al. 1998. Smad3 mutant mice develop metastatic colorectal cancer. Cell 94: 703-714.
14. DATTO, M.B. et al. 1999. Targeted disruption of Smad3 reveals an essential role in transforming growth factor beta-mediated signal transduction. Mol. Cell Biol. 19: 2495-2504.
15. ASHCROFT, G.S. et al. 1999. Mice lacking Smad3 show accelerated wound healing and an impaired local inflammatory response. Nat. Cell Biol. 1: 260-266.
16. YANG, X. et al. 1999. Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-beta. Embo J. 18: 1280-1291.
17. WOLFRAIM, L.A. et al. 2004. Loss of Smad3 in acute T-cell lymphoblastic leukemia. N. Engl. J. Med. 351: 552-559.
18. SHAY, J.W. & S. BACCHETTI. 1997. A survey of telomerase activity in human cancer. Eur. J. Cancer 33: 787-791.
19. BLACKBURN, E.H. 2001. Switching and signaling at the telomere. Cell 106: 661-673.
20. DE LANGE, T. 1998. Telomeres. Nature 392: 753-754.
21. COLLINS, K. & J.R. MITCHELL. 2002. Telomerase in the human organism. Oncogene 21: 564-579.
22. HARLEY, C.B. 2002. Telomerase is not an oncogene. Oncogene 21: 494-502.
23. BLASCO, M.A. 2002. Opinion: telomerase beyond telomeres. Nat. Rev. Cancer 2: 627-633.
24. BLACKBURN, E.H. 2005. Telomeres and telomerase: their mechanisms of action and the effects of altering their functions. FEBS Lett. 579: 859-862.
25. MEYERSON, M. et al. 1997. hEst2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 90: 785-795.
26. NAKAMURA, T.M. et al. 1997. Telomerase catalytic subunit homologs from fission yeast and human. Science 277: 955-959.
27. SHAY, J.W. & W.E. WRIGHT. 2005. Mechanism-based combination telomerase inhibition therapy. Cancer Cell 7: 1-2.
28. KELLAND, L.R. 2005. Overcoming the immortality of tumour cells by telomere and telomerase based cancer therapeutics-current status and future prospects. Eur. J. Cancer 41: 971-979.
29. LI, S. et al. 2005. Cellular and gene expression responses involved in the rapid growth inhibition of human cancer cells by RNA interference-mediated depletion of telomerase RNA. J. Biol. Chem. 280: 23709-23717.
30. DIKMEN, Z.G. et al. 2005. In vivo inhibition of lung cancer by GRN163L: a novel human telomerase inhibitor. Cancer Res. 65: 7866-7873.
31. GELLERT, G.C. et al. 2006. Effects of a novel telomerase inhibitor, GRN163L, in human breast cancer. Breast Cancer Res. Treat. 96: 73-81.
32. CAO, Y. et al. 2002. Telomerase activation causes vascular smooth muscle cell proliferation in genetic hypertension. FASEB J. 16: 96-98.
33. LI, H. et al. 2005. Telomerase down-regulation does not mediate PC12 pheochromocytoma cell differentiation induced by NGF, but requires MAP kinase signalling. J. Neurochem. 95: 891-901.
34. LI, H. et al. 2006. Transforming growth factor beta suppresses human telomerase reverse transcriptase (hTERT) by Smad3 interactions with c-Myc and the hTERT gene. J. Biol. Chem. 281: 25588-25600.
35. BESTILNY, L.J. et al. 1996. Selective inhibition of telomerase activity during terminal differentiation of immortal cell lines. Cancer Res. 56: 3796-3802.
36. HOLT, S.E. et al. 1996. Regulation of telomerase activity in immortal cell lines. Mol. Cell Biol. 16: 2932-2939.
37. TZUKERMAN, M. et al. 2000. Identification of a novel transcription factor binding element involved in the regulation by differentiation of the human telomerase (hTERT) promoter [in process citation]. Mol. Biol. Cell 11: 4381-4391.
38. PARSCH, D. et al. 2004. Telomere length and telomerase activity during expansion and differentiation of human mesenchymal stem cells and chondrocytes. J. Mol. Med. 82: 49-55.
39. ARMSTRONG, L. et al. 2004. A role for nucleoprotein Zap3 in the reduction of telomerase activity during embryonic stem cell differentiation. Mech. Dev. 121: 1509-1522.
40. NOZAWA, K. et al. 2001. Mechanism for the reduction of telomerase expression during muscle cell differentiation. J. Biol. Chem. 276: 22016-22023.
41. LIU, L. et al. 2004. Telomerase inhibition by retinoids precedes cytodifferentiation of leukemia cells and may contribute to terminal differentiation. Mol. Cancer Ther. 3: 1003-1009.
42. LIU, J.P. 1999. Studies of the molecular mechanisms in the regulation of telomerase activity. FASEB J. 13: 2091-2104.
43. LIU, J.P. 2001. Molecular mechanisms regulating telomerase activity. In Telomerase, Aging and Disease. M.P. Mattson & T. Pandita, Eds.: 33-59. Elsevier Science. Amsterdam, the Netherlands.
44. LIU, J.P. et al. 2002. Regulation of telomerase activity. In Telomeres and Telomerases: Cancer and Biology. G. Krupp & R. Parwaresch, Eds.: 134-159. Landes Bioscience/Eurekah. Austin, TX.
45. CONG, Y.S. et al. 1999. The human telomerase catalytic subunit hTERT: organization of the gene and characterization of the promoter [in process citation]. Hum. Mol. Genet. 8: 137-142.
46. MAC, S.M. et al. 2000. Direct recruitment of N-myc to target gene promoters. Mol. Carcinog. 29: 76-86.
47. EBERHARDY, S.R. et al. 2000. Direct examination of histone acetylation on Myc target genes using chromatin immunoprecipitation. J. Biol. Chem. 275: 33798-33805.
48. KYO, S. et al. 2000. Sp1 cooperates with c-Myc to activate transcription of the human telomerase reverse transcriptase gene (hTERT) [in process citation]. Nucleic Acids Res. 28: 669-677.
49. ADHIKARY, S. & M. EILERS. 2005. Transcriptional regulation and transformation by Myc proteins. Nat. Rev. Mol. Cell Biol. 6: 635-645.
50. WU, K.J. et al. 1999. Direct activation of TERT transcription by c-MYC. Nat. Genet. 21: 220-224.
51. XU, D. et al. 2001. Switch from Myc/Max to Mad1/Max binding and decrease in histone acetylation at the telomerase reverse transcriptase promoter during differentiation of HL60 cells. Proc. Natl. Acad. Sci. USA 98: 3826-3831.
52. YAGO, M. et al. 2002. Variant forms of upstream stimulatory factors (USFs) control the promoter activity of hTERT, the human gene encoding the catalytic subunit of telomerase. FEBS Lett. 520: 40-46.
53. TAKAKURA, M. et al. 2005. Function of AP-1 in transcription of the telomerase reverse transcriptase gene (TERT) in human and mouse cells. Mol. Cell. Biol. 25: 8037-8043.
54. ARMSTRONG, L. et al. 2005. Overexpression of telomerase confers growth advantage, stress resistance, and enhanced differentiation of ESCs toward the hematopoietic lineage. Stem Cells 23: 516-529.
55. LEE, M.K. et al. 2005. Ectopic mTERT expression in mouse embryonic stem cells does not affect differentiation but confers resistance to differentiation- and stress-induced p53-dependent apoptosis. J. Cell Sci. 118: 819-829.
56. WANG, J. et al. 2005. Human telomerase reverse transcriptase immortalizes bovine lens epithelial cells and suppresses differentiation through regulation of the ERK signaling pathway. J. Biol. Chem. 280: 22776-22787.
57. KATAKURA, Y. et al. 1999. Transforming growth factor beta triggers two independent-senescence programs in cancer cells. Biochem. Biophys. Res. Commun. 255: 110-115.
58. VIJAYACHANDRA, K. et al. 2003. Smad3 regulates senescence and malignant conversion in a mouse multistage skin carcinogenesis model. Cancer Res. 63: 3447-3452.
59. DEBACQ-CHAINIAUX, F. et al. 2005. Repeated exposure of human skin fibroblasts to UVB at subcytotoxic level triggers premature senescence through the TGF-beta1 signaling pathway. J. Cell Sci. 118: 743-758.
60. NOZAKI, Y. et al. 2000. Induction of telomerase activity in fibroblasts from bleomycin-injured lungs. Am. J. Respir. Cell Mol. Biol. 23: 460-465.
61. YANG, H. et al. 2001. Autocrine transforming growth factor beta suppresses telomerase activity and transcription of human telomerase reverse transcriptase in human cancer cells. Cell Growth Differ. 12: 119-127.
62. CEREZO, A. et al. 2002. Dual regulation of telomerase activity through c-Myc-dependent inhibition and alternative splicing of hTERT. J. Cell Sci. 115: 1305-1312.
63. LIU, T. et al. 2002. Regulation of telomerase activity in rat lung fibroblasts. Am. J. Resp. Cell Mol. Biol. 26: 534-540.
64. LIN, S.Y. & S.J. ELLEDGE. 2003. Multiple tumor suppressor pathways negatively regulate telomerase. Cell 113: 881-889.
65. LI, H. et al. 2006. TGF-beta and cancer: is Smad3 a repressor of hTERT gene? Cell Res. 16: 169-173.
66. HU, B. et al. 2006. Role of Smad3 in the regulation of rat telomerase reverse transcriptase by TGFbeta. Oncogene 25: 1030-1041.
67. MATSUURA, I. et al. 2004. Cyclin-dependent kinases regulate the antiproliferative function of Smads. Nature 430: 226-231.
68. KAMARAJU, A.K. & A.B. ROBERTS. 2005. Role of Rho/ROCK and p38 MAP kinase pathways in transforming growth factor-beta-mediated Smad-dependent growth inhibition of human breast carcinoma cells in vivo. J. Biol. Chem. 280: 1024-1036.
69. MASSAGUE, J. et al. 2005. Smad transcription factors. Genes Dev. 19: 2783-2810.
70. DANIELPOUR, D. & K. SONG. 2006. Cross-talk between IGF-I and TGF-beta signaling pathways. Cytokine Growth Factor Rev. 17: 59-74.
71. STAMPFER, M.R. et al. 1997. Gradual phenotypic conversion associated with immortalization of cultured human mammary epithelial cells. Mol. Biol. Cell. 8: 2391-2405.
72. STAMPFER, M.R. et al. 2001. Expression of the telomerase catalytic subunit, hTERT, induces resistance to transforming growth factor beta growth inhibition in p16INK4A(-) human mammary epithelial cells. Proc. Natl. Acad. Sci. USA 98: 4498-4503.
73. ZHANG, H. & S.N. COHEN. 2004. Smurf2 up-regulation activates telomere-dependent senescence. Genes Dev. 18: 3028-3040.
74. XU, D. et al. 2006. Inhibition of telomerase targeting MAP kinase signaling. In Methods in Molecular Biology: telomerase Inhibition: strategies and Protocols. L.G. Andrews & T.O. Tollefsbol, Eds.: in press. Humana Press Inc. Totowa; NJ.
75. DWYER, J., LI, H., XU, D. & LIU, J-P. 2007. Transcriptional regulation of telomerase activity: roles of the Ets transcription factor family. Ann. N.Y. Acad. Sci. This volume.
76. LIBERATI, N.T. et al. 1999. Smads bind directly to the Jun family of AP-1 transcription factors. Proc. Natl. Acad. Sci. USA 96: 4844-4849.